AstraZeneca PLC AZN has struck a deal to buy a portfolio of gene therapies from Pfizer Inc. PFE for up to $1 billion, the biopharma company announced Friday.

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot wants to move the drugmaker’s stock listing to the US, the Times reported, in what would be another sign of the UK’s waning status as ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.

AstraZeneca has announced a new clinical study titled ‘Exacerbations and Their Outcomes in Egyptian Patients (EXACOS EG Population),’ which aims to explore the burden of severe exacerbations ...

Since AstraZeneca has quite a presence in the U.S. healthcare market and does much of its business in the country, it makes abundant sense to shift the main stock market listing and even the ...

(Reuters) -AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the ...

AstraZeneca, Daiichi Sankyo obtain FDA nod for Datroway Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar ...

The article that dinged AstraZeneca was a Bloomberg piece asserting that the company is in discussions with Summit Therapeutics (SMMT -5.18%) on a formal partnership. Image source: Getty Images.

AstraZeneca PLC (NASDAQ: AZN) announced Monday that its investigational drug baxdrostat met both the primary and all secondary endpoints in the BaxHTN Phase III clinical trial for patients with ...